Hoth Net Debt To E B I T D A from 2010 to 2024

HOTH Stock  USD 0.85  0.01  1.16%   
Hoth Therapeutics' Net Debt To EBITDA is increasing with slightly volatile movements from year to year. Net Debt To EBITDA is estimated to finish at 57.00 this year. Net Debt To EBITDA is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). View All Fundamentals
 
Net Debt To EBITDA  
First Reported
2010-12-31
Previous Quarter
54.28
Current Value
57
Quarterly Volatility
23.49736731
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Hoth Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hoth Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 742, Interest Expense of 368.8 K or Selling General Administrative of 4.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.53. Hoth financial statements analysis is a perfect complement when working with Hoth Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Hoth Therapeutics Correlation against competitors.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

Latest Hoth Therapeutics' Net Debt To E B I T D A Growth Pattern

Below is the plot of the Net Debt To E B I T D A of Hoth Therapeutics over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Hoth Therapeutics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hoth Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Debt To E B I T D A10 Years Trend
Slightly volatile
   Net Debt To E B I T D A   
       Timeline  

Hoth Net Debt To E B I T D A Regression Statistics

Arithmetic Mean11.85
Geometric Mean1.22
Coefficient Of Variation198.26
Mean Deviation18.14
Median0.61
Standard Deviation23.50
Sample Variance552.13
Range60.2017
R-Value0.69
Mean Square Error312.56
R-Squared0.47
Significance0
Slope3.62
Total Sum of Squares7,730

Hoth Net Debt To E B I T D A History

2024 57.0
2023 54.28
2022 60.32
2020 0.36
2019 0.22
2018 0.11

About Hoth Therapeutics Financial Statements

Investors use fundamental indicators, such as Hoth Therapeutics' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Hoth Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Debt To EBITDA 54.28  57.00 

Currently Active Assets on Macroaxis

When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:
Check out the analysis of Hoth Therapeutics Correlation against competitors.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Return On Assets
(0.46)
Return On Equity
(0.83)
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.